anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study is to test whether dietary antioxidant supplementation can alter the expression in lung epithelial cells of genes related to oxidant response and whether this response is dependent on factors such as the individual's baseline serum antioxidant status, dietary antioxidant status, and the oxidant/anti-oxidant balance in the lung. The underlying hypothesis is that the intake of vitamins with antioxidant properties (selenomethionine, vitamin E and vitamin C) will boost the antioxidant levels of the airway epithelium sufficient to protect the epithelium from the stress of oxidants in cigarette smoke. Our prior work shows that phenotypic normal smokers (cigarette smokers with normal history, physical exam, lung function tests, and chest x-rays) have marked up and down regulation of \> \~200 genes in the airway epithelium. The proposed project will build on past findings by examining whether regulation of gene expression responds to changes in nutritional status. The primary aim will be assessment of gene expression of the airway epithelium (from protocol #0005004439 entitled "Evaluation of the Lungs of Normal (Smokers, Ex-smokers, Non-Smokers) Individuals with Segmental Bronchopulmonary Lung Lavage, Bronchial Brushing, and Bronchial Wall Biopsy") obtained before and after taking standard amounts of selenomethionine, vitamin E and vitamin C, or placebo for 30 days. The secondary aims will be to evaluate the ability of vitamin supplementation to raise lung and serum vitamin levels, to reduce the oxidant stress in the lung and systemically (as measured by lung and urinary F2 isoprostane levels, respectively), and to assess the vitamin-induced change in airway epithelial gene expression in genes other than oxidant related genes.
Compounds of general formula (I) are useful for treating mental disorders, wherein R 1  and R 2  are the same or different and selected from hydrogen or lower alkyl; Ar are the same or different and selected from pyridyl and phenyl groups, n is 1 or 2, X is nitrogen or methine. When X is nitrogen, Y is methylene. When X is methine, Y is selected from nitrogen or oxygen. A is selected from carboxylic derivatives. The pharmacologically active salts of formula (I) are also embraced. ##STR1##
A sample of 350 HIV-uninfected women who are not currently pregnant, in a stable relationship (≥6 months) with a self-reported infected or unknown serostatus partner and personal or partner plans for pregnancy in the next 12 months. Women will be offered safer conception counseling based on South African guidelines plus daily, oral tenofovir/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) during periconception and pregnancy.
The present invention relates to a large-scale preparation method for compound nanoparticles. The compound nanoparticles are prepared from human serum albumin and polylactic acid by means of an emulsion-solvent evaporation method. The preparation method comprises: (1) high-speed shearing and mixing; (2) high-pressure homogenization; (3) removal of an organic solvent under reduced pressure; (4) tangential flow purification; and (5) membrane filtration and sterilization. The mass ratio of the human serum albumin to the polylactic acid is (1-12):1. The polylactic acid is selected from ester-terminated poly-L-lactic acid, carboxyl-terminated poly-L-lactic acid, and ester-terminated poly-D,L-lactic acid. The particle size of the compound nanoparticles obtained by means of the preparation method is smaller than 130 nm and has good uniformity, such that the compound nanoparticles have relatively high protein loading capacity and stability, thereby solving the problems that a laboratory ultrasonic preparation method has poor repeatability and a poor emulsifying effect, is incapable of achieving large-scale preparation, and the like.
The invention belongs to the field of communicable disease prevention and cure, and particularly relates to a candidated autoantigen of vaccine for blocking malignant malaria transmission. According to the invention, a gene recombination method is used for constructing a plasmodium falciparum pfs25 protein dipolymer derivative, and the dipolymer derivative comprises two pfs25 protein units which are connected through a connection arm. The obtained dipolymer derivative strengthens immunogenicity of pfs25 proteins, and can arouse high antibody response in an animal body. Dipolymers can be produced by recombination yeast cells in a high-expression mode and secreted to a culture medium. An expression product with even compositions is obtained after purification, and the expression product can be applicable to mass production. The plasmodium falciparum pfs25 protein dipolymer derivative is expected to be candidated antigens of blocked vaccines of the malignant malaria transmission.
The invention discloses a method for biomimetic simulated synthesis of a photothermal tumor combined treatment nano preparation. The main steps comprise 1) preparing PLGA organic solution; 2) Synthesizing (SEV + aCD 47) @ PLGA nano-particles by a thin film hydration method. Sendai virus (SEV) can activate organism immunity, and kill and eliminate tumor in all directions. The aCD47 can block a signaling pathway between CD47 and SIRPa, and activate the ability of macrophages to phagocytose tumor cells. Aggregation-induced emission (AIE), which is highly efficient in its aggregated state, visualizes the tumor treatment process. PLGA has good biocompatibility, no toxicity, and good properties of encapsulation and film formation, and is widely applied to the fields of pharmacy, medical engineering materials and modern industry. The composite nano-particle for the collective virus immunotherapy can improve the effect of tumor therapy.
Full thickness mucoperiosteal flap was elevated.• The pilot drill of the implant system was used to create an osteotomy 1 mm short of the subantral floor. • The insertion of the osteotome were repeated several times until the required membrane lift was achieved then the osteotome corresponding in size to the last drill was used.After that, placement of the implant was done .Healing abutment was placed to allow for multiple times measurements of implant stability and primary closure was done and the flap was sutured in an interrupted manner using 4/0 prolene suture .
OBJECTIVES: Fetal hypoxia due to placental dysfunction is the hallmark of fetal growth restriction (FGR). Preferential perfusion of the brain (brain-sparing effect), as a part of physiological placental cardiovascular compensatory mechanisms to hypoxia, in FGR was reported. Therefore, the correlation between vascular endothelial growth factor A (VEGF-A) protein expression in the FGR placentas and newborns' early neurological outcome was examined.
METHODS: This study included 50 women with FGR complicated pregnancies and 30 uneventful pregnancies. Fetal hemodynamic parameters, neonatal acid-base status after delivery, placental pathohistology and VEGF-A expression were followed. Early neonatal morphological brain evaluation by ultrasound and functional evaluation of neurological status by Amiel - Tison Neurological Assessment at Term (ATNAT) were performed.
RESULTS: VEGF-A protein expression level was significantly higher in the FGR placentas than normal term placentas (Fisher-Freeman-Halton's test, p≤0.001). No statistically significant correlation between placental VEGF-A expression and different prenatal and postnatal parameters was noticed. Whereas the alteration of an early neurological status assessed by ATNAT was found in 58 % of FGR newborns, morphological brain changes evaluated by UZV was noticed in 48 % of cases. No association between the level of placental VEGF-A expression and the early neurological deficits was found.
CONCLUSIONS: As far as we know this is the first study of a possible connection between VEGF-A protein expression in the FGR placentas and neonates' early neurological outcomes. The lack of correlation between the FGR placental VEGF-A expression and neonates' neurological outcome could indicate that optimal early neurodevelopment may take place due to compensatory mechanism not related to placental VEGF-A expression.
The invention relates to mango starch and a preparation method and applications thereof. The mango starch is prepared by adopting immature mango pulp as a raw material through a peeling and denucleating step, a pulping step, an acidity adjustment step, a filtering step, a centrifuging step and a drying step. The mango starch is white and fine and smooth. Compared with other kinds of common starch, the mango starch is smaller in particle size and is better in retention property and solubility property. When foodstuffs, health-care products or medicines are prepared, better processability can be provided, so that the mango starch is better in mouthfeel. As the starch product is rich in variety, the waste of fresh mango is reduced.
A Multicenter, One group, Open-label Study. Cilostazol will be treated for additional 24 weeks to the subject who had completed 021-KOA-1301i study. PletaalÒ(Cilostazol) is taken 100mg oral tablets bid during 2 3weeks after dosing of PletaalÒ(Cilostazol) 50mg oral tablets bid during 1 week. The dose can be adjusted by investigator's discretion during the study and the detailed method is described in the Protocol. Subject who has 2 or more chest pain at 4th week will be withdrawn from the study (But, subjects who show 50% or more of chest pain decrease compared to 1st week would not be withdrawn.). Subjects who participated in this trial will have 2 weeks follow-up after study completion.
Patients receive zirconium Zr 89-Df-crefmirlimab IV over 5-10 minutes and then under PET imaging 24 hours after infusion before and after SBRT. Patients undergo SBRT every 2-5 days for a total of 5 fractions. For lymphoma patients only, IMRT on consecutive days may be used.
The invention discloses a CD16a specific antibody, a derivative thereof and application thereof. The present invention provides CD16 a-specific antibodies, the heavy and light chain variable regions of which are shown in SEQ ID NO. 1-28. The invention also provides miniaturized antibodies to antibodies specific for CD16 a. The invention also provides functionalized antibodies to CD16 a-specific antibodies or functionalized antibodies to miniaturized antibodies to CD16 a-specific antibodies. The invention also provides the use of CD16a specific antibodies or miniaturized antibodies to CD16a specific antibodies. The use is to bind CD16a or to prepare a product for binding CD16 a. The invention also provides the use of a functionalized antibody of a CD16a specific antibody or a functionalized antibody of a miniaturized antibody of a CD16a specific antibody. The use is as a medicament or in the manufacture of a medicament. The invention has great value in the field of medicine.
PURPOSE: A composition containing a medicinal herb material extract as an active ingredient is provided to induce angiogenesis, to promote blood circulation, to prevent and treat vein aging and skin aging. CONSTITUTION: A composition for promoting angiogenesis contains one or more selected from a group consisting of a Forsythia suspense Vahl extract, a Croton tiglium extract, and a Taraxacum mongolium Hand.-Mazz extract. A composition for treating angiogenesis-dependent diseases or improve blood circulation contains one or more selected from a group consisting of the extracts. The angiogenesis-dependent diseases are selected from a group consisting of atherosclerosis and ischemic heart disease. A composition for treating vein aging or skin aging contains one or more selected from a group consisting of the extracts. A composition for promoting wound healing contains one or more selected from a group consisting of the extracts. Each extract is prepared using one or more solvents selected from water, alcohol, and a hydrocarbon-bases solvent. [Reference numerals] (AA) Control group; (BB) Forsythia suspense Vahl; (CC) Croton tiglium; (DD) Taraxacum mongolium Hand.-Mazz; (EE) Corydalis ternata Nakai
PURPOSE: To evaluate sex-based differences in 30-day postoperative emergency department (ED) visits, 90-day complication rates, and 2-year secondary surgery rates after the Latarjet procedure for the treatment of recurrent shoulder instability.
METHODS: A national administrative claims database was used to identify patients with International Classification of Diseases, Tenth Revision (ICD-10) diagnosis codes for shoulder subluxation or dislocation on the day of first-time stabilization with the Latarjet technique between 2015 and 2021. Male patients were matched 4:1 to female patients based on age, Elixhauser Comorbidity Index (ECI) score, and body mass index class. Rates of 30-day ED visits and 90-day complications were compared between cohorts, and risk factors for ED visits were identified by multivariate regression. The incidence of secondary surgery within 2 years was compared by Kaplan-Meier analysis.
RESULTS: Prior to matching, 1,059 male and 360 female patients met the inclusion and exclusion criteria. Subsequent 4:1 (male-to-female) matching controlling for age, ECI score, and body mass index yielded 694 male and 185 female patients who underwent the Latarjet procedure. The overall incidence of 30-day ED visits was 9.3%, with an incidence of 8.2% for male patients and 13.5% for female patients. On the basis of multivariate logistic regression, these 30-day ED visits were associated with female sex (odds ratio, 1.79; P = .029) and incrementally higher ECI scores; relative to an ECI score of 0, ECI scores of 1 to 2, 3 to 4, and 5 or greater were associated with odds ratios of 5.31 (P = .006), 8.12 (P < .001), and 12.84 (P < .001), respectively. Ninety-day complications occurred in 1.5% of the total cohort, and the incidence was not statistically different between sexes. Overall, 2-year secondary surgery rates were similar between male and female patients (5.1% and 6.7%, respectively; P = .4).
CONCLUSIONS: Female patients undergoing the Latarjet procedure for recurrent shoulder instability showed similar 90-day complication and 2-year secondary surgery rates to a matched cohort of male patients. Female sex, along with ECI score, however, was associated with a greater rate of 30-day ED visits.
LEVEL OF EVIDENCE: Level III, retrospective comparative case series.
BACKGROUND: Recurrence of focal segmental glomerulosclerosis (FSGS) or steroid-resistant nephrotic syndrome (SRNS) after kidney transplant leads to significant morbidity and potentially earlier allograft loss. To date however, reported rates, risk factors and treatment outcomes have varied widely.
METHODS: We applied computational phenotypes to a multicenter aggregation of electronic health records data from 7 large pediatric health systems in the USA, to identify recurrence rates, risk factors, and treatment outcomes. We refined the data collection by chart review.
RESULTS: From > 7 million patients, we compared children with primary FSGS/SRNS who received a kidney transplant between 2009 and 2020 and who either developed recurrence (n = 67/165; 40.6%) or did not (n = 98/165). Serum albumin level at time of transplant was significantly lower and recipient HLA DR7 presence was significantly higher in the recurrence group. By 36 months post-transplant, complete remission occurred in 58.2% and partial remission in 17.9%. Through 6 years post-transplant, no remission after recurrence was associated with an increased risk of allograft loss over time (p < 0.0001), but any remission showed similar allograft survival and function decline to those with no recurrence. Since treatments were used in non-random fashion, using spline curves and multivariable non-linear analyses, complete + partial remission chance was significantly higher with greater plasmapheresis sessions, CTLA4-Ig doses or LDL-apheresis sessions. Only treatment with anti-CD20, CTLA4-Ig agents, or LDL-apheresis sessions were associated with complete remission. Excluding 25 patients with mutations did not significantly change our results.
CONCLUSIONS: Our contemporary high-risk cohort had higher favorable response rates than most prior reports, from combinations of agents.
RO5024048 1000mg bid + Pegasys + Copegus for 12 weeks, followed by SOC for 12 weeks. After 24 weeks, patients who have achieved rapid viral response will stop treatment, and those who have not will receive SOC for a further 24 weeks.
Spontaneous bacterial peritonitis (SBP) is a severe complication in patients with decompensated liver cirrhosis and is commonly treated with broad spectrum antibiotics. However, the rise of antibiotic resistance requires alternative therapeutic strategies. As recently shown, human amnion-derived mesenchymal stem cells (hA-MSCs) are able, in vitro, to promote bacterial clearance and modulate the immune and inflammatory response in SBP. Our results highlight the upregulation of FOXO1, CXCL5, CXCL6, CCL20, and MAPK13 in hA-MSCs as well as the promotion of bacterial clearance, prompting a shift in the immune response toward a Th17 lymphocyte phenotype after 72 h treatment. In this study, we used an in vitro SBP model and employed omics techniques (next-generation sequencing) to investigate the mechanisms by which hA-MSCs modify the crosstalk between immune cells in LPS-stimulated ascitic fluid. We also validated the data obtained via qRT-PCR, cytofluorimetric analysis, and Luminex assay. These findings provide further support to the hope of using hA-MSCs for the prevention and treatment of infective diseases, such as SBP, offering a viable alternative to antibiotic therapy.
In patients with shock a primary goal of treatment is to restore and maintain organ perfusion, for which an adequate cardiac preload is required. Apart from the situations in which hypovolemia is evident and a favourable response to fluid administration will be seen, clinical and biological parameters often fail to predict hypovolemia. Inappropriate use of volume expansion carries out the risk of generating volume overload and pulmonary oedema. Consequently, reliable predictors of fluid responsiveness are needed especially in the early phase of cardiocirculatory deterioration. In the clinical setting, different static and dynamic indices have been shown to be useful indicators of cardiac preload. Central venous pressure (CVP) is widely used to measure right ventricular preload in patients requiring invasive hemodynamic monitoring. However, the use of the CVP is much criticized because CVP poorly predicts cardiac preload and volume status. However several decades ago, Weil and Henning proposed the fluid challenge technique, based on the 2-5 rule using CVP. There is a method for guiding volume repletion based on measurements of the patient's response to fluid load. This method has not been validated in the prediction of fluid responsiveness. We therefore conducted a prospective study that in all patients we measured CVP change and stroke volume variation (SVV) after administration of fluids. Patients were classified as fluid responders when their SVV is \>10% after volume expansion and non-responders if SVV is ≤10%.
Hydroxyzine hydrochloride intramuscular solution is intended only for intramuscular administration and should not, under any circumstances, be injected subcutaneously, intra­ arterially or intravenously.

Hydroxyzine is contraindicated in patients with a prolonged QT interval.

This drug is contraindicated for patients who have shown a previous hypersensitivity to it.

Hydroxyzine, when administered to the pregnant mouse, rat, and rabbit, induced fetal abnormalities in the rat at doses substantially above the human therapeutic range. Clinical data in human beings are inadequate to establish safety in early pregnancy. Until such data are available, hydroxyzine is contraindicated in early pregnancy.
Selective absorbent for binding immune complexes (A) from body fluids by biospecific reaction comprises an SiO2-material as solid phase. This phase is reacted with protein C1q, either directly or after modifying the surface with a silane adhesion promoter and a hetero- or homo-bifunctional reagent. After binding of (A) to the immobilised C1q, by perfusion of the body fluid (e.g. blood or plasma), the solid phase is sepd. and regenerated for reuse of treatment with a non-denaturing medium. - Pref. the SiO2 material comprises shaped articles, e.g. beads or fibres, of glass or glassy material.
ETHNOPHARMACOLOGICAL RELEVANCE: When left untreated, liver fibrosis (LF) causes various chronic liver diseases. Earthworms (Pheretima aspergillum) are widely used in traditional medicine because of their capacity to relieve hepatic diseases.
AIM OF THE STUDY: This study aimed to explore the anti-LF effects of water extract of earthworms (WEE) and the underlying molecular mechanisms.
MATERIALS AND METHODS: A CCl4-induced mouse model of LF was used to study the impact of WEE on LF in vivo. The anti-LF activity of WEE in mice was compared with that of silybin, which can be clinically applied in LF intervention and was used as a positive control. Activation of LX-2 hepatic stellate cells (HSCs) and apoptosis and ferroptosis of AML-12 hepatocytes induced by TGFβ1 were used as in vitro models.
RESULTS: WEE drastically improved LF in mice. WEE reduced markers of activated HSCs in mice and inhibited TGFβ1-induced activation of LX-2 HSCs in vitro. Additionally, WEE suppressed CCl4-induced apoptosis and ferroptosis in mouse hepatocytes. Mechanistically, WEE induced Nrf2 to enter the nuclei of the mouse liver cells, and the hepatic levels of Nrf2-downstream antioxidative factors increased. LKB1/AMPK/GSK3β is an upstream regulatory cascade of Nrf2. In the LF mouse model, WEE increased hepatic phosphorylated LKB1, AMPK, and GSK3β levels. Similar results were obtained for the LX-2 cells. In AML-12 hepatocytes and LX-2 HSCs, WEE elevated intracellular Nrf2 levels, promoted its nuclear translocation, and inhibited TGFβ1-induced ROS accumulation. Knocking down LKB1 abolished the impact of WEE on the AMPK/GSK3β/Nrf2 cascade and eliminated its protective effects against TGFβ1.
CONCLUSIONS: Our findings reveal that WEE improves mouse LF triggered by CCl4 and supports its application as a promising hepatoprotective agent against LF. The potentiation of the hepatic antioxidative AMPK/GSK3β/Nrf2 cascade by activating LKB1 and the subsequent suppression of HSC activation and hepatocyte apoptosis and ferroptosis are implicated in WEE-mediated alleviation of LF.
Participants receive IMC-F106C Low Dose once weekly (QW) for the first 12 weeks, then every 2 weeks (Q2W) through Week 51, and then every 4 weeks (Q4W) until Week 101. Nivolumab is given Q4W until Week 101.
A method for displaying a computer-generated determination of the overall likelihood of malignancy in a mammogram lesion. The method requires providing a digitized image of a mammogram, displaying the digitized image, and selecting a region of interest directly on the displayed digitized image. The digitized image is then processed so that classifier data of the lesion in the user-selected region of interest are generated and displayed. The overall likelihood of malignancy is generated from the classifier data and also displayed. A clinical recommendation for further assessing the lesion is derived from the overall evaluation of malignancy and presented to the user. A system for displaying a determination of the overall likelihood of malignancy in a mammogram lesion and for presenting a clinical recommendation to the user is also provided. A method for integrating the overall likelihood of malignancy with a physician's independent score for the lesion is discussed.